Eisai signs lorcaserin deal in China

1 August 2018

Japanese drug major Eisai (TYO: 4523) has granted exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (US brand name Belviq) in China (including Hong Kong and Macao) to Taiwan-headquartered CY Biotech (Taiwan-headquartered.

Under this agreement, Eisai will supply CYB with lorcaserin. Eisai will receive a one-time contractual payment and milestone payments dependent upon acquisition of regulatory approval. In addition, Eisai has the option rights to co-promote lorcaserin with CYB in China (excluding Hong Kong and Macao), as well as the option rights to market lorcaserin in Hong Kong and Macao.

USA-based Arena Pharmace Publishuticals (Nasdaq: ARNA), the developer of the drug, launched Belviq in the USA in June 2013. Lorcaserin was approved in Mexico in July 2016 and in Brazil in December 2016, with the same indication as for the USA. In Taiwan, lorcaserin was developed by CYB, which obtained approval in July 2017 and launched lorcaserin in Taiwan in October 2017. In January 2017, Eisai acquired rights to the product from Arena.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK